Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action.
about
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporterA human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPsTests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messengerVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryHow addictive drugs disrupt presynaptic dopamine neurotransmissionVesicular monoamine transporter 2: role as a novel target for drug developmentRole of monoamine transporters in mediating psychostimulant effectsNorepinephrine and stimulant addictionPresynaptic dopamine modulation by stimulant self-administrationMechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.Pharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.Glial modulators as potential treatments of psychostimulant abuseVMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicitySerial analysis of gene expression in the rat striatum following methamphetamine administrationDopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamineRats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbensBehavioral genetic contributions to the study of addiction-related amphetamine effects.meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine releaseRole of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity.Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum.Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Vmat2 heterozygous mutant mice display a depressive-like phenotype.Regulation of quantal size by presynaptic mechanisms.Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.Molecular mechanisms of amphetamine actions in Caenorhabditis elegansSex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride.Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine.Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.Amphetamine potency varies with dopamine uptake rate across striatal subregions.Attention deficit/hyperactivity disorder: pharmacotherapy.Adaptations of presynaptic dopamine terminals induced by psychostimulant self-administration.Striatal dopamine neurotransmission: regulation of release and uptakePhenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.
P2860
Q24314400-45B8EFC9-6B1F-4689-A49B-6A3D276F23C8Q24321541-16BFDC62-ADAF-4EEC-982D-08C0B46E6BB2Q24559960-0D565EC1-8E90-4ACB-9FFD-A50992115A69Q24601233-C5F71CDE-CFDB-430D-913A-0028D2EE8751Q24631269-93F90DE8-5A27-450A-8B0A-696FB2ECE599Q24647764-5BDF98CB-8A5C-4F7E-A5DB-844AE36FF4ADQ24647948-29130C19-CDEC-4135-BF26-CDED0A258A03Q24656833-E7310CFE-A687-4340-A94B-00D23EABC3D1Q26823507-560722DB-FB58-4D90-BAA1-A354D0F8FFE1Q27333086-C803ED34-509B-4134-A3A0-D93599A1E71CQ27687469-0C7014B6-92C5-48A6-AFC3-E428D8242118Q28307030-BB09570B-9914-46FC-8EE2-F9DBAB63B1BFQ28512294-6E879272-7509-492F-9D05-FBBDCF17C91BQ28574873-0C5CE51E-92AA-4604-AFE9-7A142CA8E8DDQ30372768-97E9FD6C-12C0-45DE-AFC3-BEE1385CFE56Q30417935-CA7BA352-78B1-4ED4-9635-F95EE58C72BFQ30493813-EF34D5C6-4D72-4C32-A119-3B74B9475085Q30494693-746C5E66-53F4-4DCF-B16D-777F0558EFA0Q30498938-5C045BCE-DDF7-4CE2-B45F-807A5A3C62BFQ31992475-5B9D9D2D-666A-4447-AF28-FDEEB0866D8CQ33580523-AD74675B-7DA0-4BA6-8FF3-A6453B8F5421Q33613631-A7137F2B-5D63-4D6A-A4E6-2FE0D9B27E58Q33738102-63E45A6E-1883-4A2F-AF73-673F412EF326Q33793549-5ACEAC12-05BF-4E46-BF79-38682EFB3625Q33863462-C301AC9C-D5C0-4E76-82FF-E26B890AF9EDQ33922930-435FCFA5-4EAA-44BB-8798-B85745C922C8Q34028189-02941E24-2E7D-4467-A7C2-3BA89EED03A7Q34172920-CA39C36E-3EFA-4BFD-973D-449579ADD3FFQ34202539-305FE862-986F-4FD2-8063-309FDCD76185Q34337802-BED19961-908F-456B-BB9B-8329BB32E7D1Q34359201-A20D0FEB-A33D-4506-81B7-3D57C9B87841Q34381228-CB77CCE1-905D-4624-91D6-06617B60B2F0Q34418634-488932E9-A614-4063-8851-BCA705BF3D48Q34452916-B16026D0-33DE-4699-A3B8-A78F920D36B1Q34524803-634DB076-9779-4944-8847-C14FA5EED41EQ34702317-473BAA80-9415-4126-86F2-7A2314E59BD2Q34979748-D28C2312-52EE-42B5-AFD2-62BDD1313484Q35007339-56D4284C-7F36-4B18-B09F-D84F5F5C690EQ35029193-C318F11D-DFC5-4EB0-846B-06C5253885ACQ35532072-6F620D33-73B0-46C8-B317-8930EA073754
P2860
Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Amphetamine and other psychost ...... anules: a mechanism of action.
@en
Amphetamine and other psychost ...... anules: a mechanism of action.
@nl
type
label
Amphetamine and other psychost ...... anules: a mechanism of action.
@en
Amphetamine and other psychost ...... anules: a mechanism of action.
@nl
prefLabel
Amphetamine and other psychost ...... anules: a mechanism of action.
@en
Amphetamine and other psychost ...... anules: a mechanism of action.
@nl
P1433
P1476
Amphetamine and other psychost ...... ranules: a mechanism of action
@en
P2093
P304
P356
10.1016/0896-6273(90)90339-H
P407
P577
1990-12-01T00:00:00Z